论文部分内容阅读
[目的]观察健肝散对酪氨酸-蛋氨酸-天冬氨酸-天冬氨酸(YMDD)变异的干预作用。[方法]选择慢性乙型病毒性肝炎患者104例,随机分为2组,对照组口服拉米夫定,治疗组给予拉米夫定加健肝散治疗,疗程均为12个月,分别观察肝功能、HBV-DNA、YMDD和临床症状的变化。[结果]2组在治疗后临床症状均明显改善,ALT、AST、HBV-DNA均降低,差异有统计学意义(P<0.05)。治疗后2组间各指标比较,仅ALT含量差异有统计学意义(P<0.01)。[结论]健肝散可以对拉米夫定诱发的乙型肝炎病毒YMDD变异起到明显的抑制作用。
[Objective] To observe the intervention of jiangan powder on the mutation of tyrosine-methionine-aspartic acid-aspartic acid (YMDD). [Method] A total of 104 patients with chronic hepatitis B were randomly divided into 2 groups. The control group received oral lamivudine. The patients in the treatment group received lamivudine plus jiangangan decoction for 12 months, respectively Liver function, HBV-DNA, YMDD and clinical symptoms. [Results] The clinical symptoms of the two groups were significantly improved after treatment, ALT, AST, HBV-DNA were decreased, the difference was statistically significant (P <0.05). After treatment, the indexes of ALT in the two groups were significantly different (P <0.01). [Conclusion] JG can obviously inhibit the YMDD mutation of hepatitis B virus induced by lamivudine.